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This study aims to evaluate a new Planned Adaptive® software (TomoTherapy Inc., Madison,
WI) of the helical tomotherapy system by retrospective verification and adaptive re-planning
of radiation treatment. Four patients with different disease sites (brain, nasal cavity, lungs,
prostate) were planned in duplicate using the diagnostic planning kVCT data set and MVCT
studies of the first treatment fraction with the same optimization parameters for both plan
types. The dosimetric characteristics of minimum, maximum, and mean dose to the targets
as well as to organs at risk were compared. Both sets of plans were used for calculation of
dose distributions in a water-equivalent phantom. Corresponding measurements of these
plans in phantom were carried out with the use of radiographic film and ion chamber. In the
case of the lung and prostate cancer patients, changes in dosimetric parameters compared
to data generated with the kVCT study alone were less than 2%. Certain changes for the
nasal cavity and brain cancer patients were greater than 2%, but they were explained in part
by anatomy changes that occurred during the time between kVCT and MVCT studies. The
Planned Adaptive software allows for adaptive radiotherapy planning using the MVCT studies obtained by the helical tomotherapy imaging system.
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Introduction
Helical tomotherapy (HT) (TomoTherapy Inc, Madison, WI) is a form of image guided radiation therapy in which a linear accelerator is mounted on a slip
ring gantry, similar to those used in helical CT scanners (1-6). During radiation
treatment, the patient is translated through the gantry while the beam continually rotates around the patient, providing helical delivery. Using the same x-ray
source, operated at 3.5 MV, megavoltage CT (MVCT) images can be acquired
before, during, or after daily treatment of the patient (7, 8). The MVCT acquisition is currently used at our center for daily image registration with the
planning kVCT (Brilliance Big Bore, Philips) dataset [see example in Fig. 1
(a)] and, thus, allows accurate patient re-positioning prior to daily treatments.
These MVCT studies also provide new and exciting opportunities for adaptive
radiotherapy (ART) (9, 10) by verification of delivered dose and replanning of
patients throughout their coarse of treatment.
The new Planned Adaptive® software (TomoTherapy Inc, Madison, WI) provides
tools for both dose verification and ART using the daily MVCT images acquired
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by helical tomotherapy system. The MVCT study is always
limited to a 40 cm circle of reconstruction due to the maximum tomotherapy collimator width whereas kVCT studies
usually have a 50 cm circle of reconstruction (Brillaince Big
Bore provides reliable CT numbers for up to 60 cm circle
of reconstruction). Also MVCT scans are typically shorter
in craniocaudal direction to save time and reduce the imaging dose. In order to compensate for insuffient field-of-view
of the MVCT studies and accurately calculate dose, Planned
Adaptive inserts the 40 cm round MVCT images into the
kVCT planning study by creating a merged MVCT/kVCT
image set, hencefore called “hybrid image”, for convenience.
Since kVCT studies are obtained with a slice thickness of 3
mm, and MVCT scanning on tomotherapy has possible slice
spacing of 6, 4, or 2 mm, interpolation within the MVCT is
required in order for the slice thickness of the merged image
to be a uniform 3 mm thickness. A different image-valuedensity table (IVDT) is also required for dose calculations
performed using MVCT images due to the higher beam energy of the tomotherapy unit.
Previous studies have shown that significant tumor regression may occur throughout treatment (9, 11-14) and in some
cases, organs at risk (OARs) may move into high dose regions, thus delivering more dose than initially planned for
critical tissue or underdosage of tumor volumes (11). By
adapting the plan to these changes, the OARs can be spared
of this inadvertent high dose deposition (15). Such adaptation also provides opportunities to increase organ sparing
beyond what was initially planned, or to escalate dose delivered to the tumor while maintaining the same conformal
avoidance of OARs if there is significant tumor regression
during treatment. The question of using pre-treatment images for planning has been studied for another on-board imaging device, kV cone-beam CT, by Ding et al. (16, 17).
Clinically, Planned Adaptive provides unique opportunities
for both dose verification and adaptive planning using the hybrid images already available. Dose verification allows for
dosimetric assessment of the effects of misalignment or anatomy changes, while adaptive planning, when used in conjunction with the verification doses, allows for the adaptation of
plans if the deformation or regression is considered clinically
significant. However, the current software does not correct
for the effects of anatomical deformation on dose delivered to
individual tissue elements (18).
Previously an evaluation of the Planned Adaptive software
has been done for phantom (19). The purpose of this study
is to assess quantitatively the accuracy of this software using hybrid images for cases from our clinical practice. This
was performed by retrospectively planning of four patients
who had been treated on tomotherapy using both their initial kVCT and their first day MVCT studies, assuming no
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changes in patient anatomy occurred between these two studies. Multi-fraction dose accumulation was not studied in this
preliminary work. The intent was to evaluate the possibility
to employ hybrid images for dose delivery verification and
adaptive therapy prior to their clinical usage.
Methods and Materials
Four patients with cancerous lesions at different sites (lung,
prostate, nasal cavity, and brain) who had previously been
treated at the London Regional Cancer Program using helical tomotherapy were selected retrospectively. A new hybrid image based plan was generated employing the same
dosimetric constraints used for the original HT plan. This
along with identical pitch, field width, modulation factor, and
number of optimization iterations insures that the same planning procedure is implemented for both kVCT and hybrid
image plans. The plans were optimized using the beamlet
dose computation option.
Using the actual MVCT study of the first treatment day of
each patient, hybrid images were created using the Planned
Adaptive software. The number of scanned MVCT slices is
defined by the minimum requirement of the PTV coverage.
Radiation oncologist may require imaging of some easily
identifiable anatomic feature or organ at risk. In practice, it
means around 20 MVCT slices with 6 mm interslice spacing. Verification doses were calculated for each patient and
compared to the planned doses. To accomplish this, Planned
Adaptive applies the daily delivery sinogram (based on the
original kVCT plan) in the calculation of the dose distribution on the current hybrid image. In clinical practice, it is
intended that after dose verification calculations, summation
doses (taking into account previously delivered fractions to
tissue elements) are generated. Once a summation dose has
been calculated, Planned Adaptive can allow for the modification of structures (including the generation of avoidance or
“top up” regions based on patterns of accumulated dose that
may have resulted in over- or under-dosage), and the hybrid
image set with modified structures are transferred to the tomotherapy planning station for optimization of an “adaptive”
plan to tailor the further treatments to correct for changes that
have occurred up to that point in treatment. Depending on the
clinical scenario, additional verifications and adaptive plans
can be generated to correct for further anatomy changes (i.e.,
continued weight loss or tumor regression, internal anatomy
warping). However, our current goal was not to test adaptive function as such but rather to see how close are the plan
based on kVCT image with corresponding IVDT and the plan
based on the hybrid image with IVDT for 3.5 MV beam.
In this study, we sought to verify that plan calculated on the
hybrid image obtained with the first MVCT correlates well
with the initial kVCT based plan. MVCT of the first day of
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Figure 1: Verification dose volume histograms calculated on first day MVCT study for (a) lung cancer patient, (b) nasal cavity cancer patient, (c) prostate
cancer patient, and (d) brain cancer patient. The solid lines are the DVH curves as planned, while the dashed lines are the verification DVH curves as calculated on the MVCT study. Superposition of the two sets of curves indicates equivalency of verification dose and planned dose.
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Figure 3: A slight deformation causes the minimum dose in PTV to be
improperly calculated.
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Figure 2: Hybrid image for the lung cancer patient with planned on
kVCT study (solid lines) and calculated using hybrid image (dashed lines)
isodose lines.

treatment was chosen because we assumed that no significant changes in anatomy occurred after kVCT scan and the
contours for all structures were kept the same for kVCT and
hybrid image based plans. In doing so, one would have inFigure 4: kVCT/MVCT hybrid image of brain cancer patient with a part of
the lens contoured outside of patient.
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creased confidence that adaptive plans generated later after
multi-fraction radiation delivery, based on the hybrid image
alone would be truly reflective of subsequent adapted delivery.
Isodose contours and dose volume histogram (DVH) curves
were used to quantify the differences between the plans. Each
hybrid image plan was directly compared to the kVCT plan in
order to determine the effects of the inherent lower quality of
MVCT images due to the higher beam energy.

and ion chamber point dose measurements with a cylindrical
water equivalent “cheese” phantom were performed for both
kVCT and hybrid image based plans. In order to correct for
any differences due to set-up or organ motion error (and in
doing so isolate the effects of differences in the planning
as opposed to the anatomy), the hybrid image for adaptive
planning was corrected by the automated registration shifts
used for the first day of treatment.

To verify the calculation accuracy, delivery quality assurance (DQA) procedures were performed for all patients as
an independent verification of the plans. Radiographic film

Results
Figure 1 shows the comparison of DVHs as planned (solid
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lines) with those calculated with the “verification dose” option of the Planned Adaptive software for each of the patients by applying the kVCT generated fluence map to the
first day hybrid image.
The results of kVCT vs. hybrid image based plans are presented in Tables I to IV where the maximum, minimum, median, and average dose for six selected structures were compared for the lung, prostate, nasal cavity, and brain cancer
patients. A maximum of 2% difference between the plan using the merged image and the plan using the kVCT planning
image for each parameter of the structures used for compari-
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son was considered clinically acceptable. Figure 2 shows
a lung cancer patient isodose view illustrated on the hybrid
image with kVCT study visible outside 40 cm MVCT circle.
We observe good agreement between planned (on kVCT
study) and calculated (using hybrid) image isodose lines for
a delivery fraction. DQA procedures of tomotherapy system were also used for both kVCT and hybrid image plans.
Point dose measurements provided quantitative comparison
shown in Table V. Film isodose contours exhibited good
agreement for all plans, and most point dose measurements
agreed within 2% with those predicted by the corresponding
plan. In certain cases, point dose measurement differences
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exceeded 2% due to either the low delivered dose or the high
dose gradient in this region.
Discussion
The verification dose of the nasal cavity patient (see Fig.
1b), when compared to the planned dose, shows small differences most notably for the optic chiasm, the planning target volume (PTV) and clinical target volume (CTV). The
fine structures, such as nasal cavities, on the MVCT images
are blurred due to the lower image quality of the hybrid image study. The blurring results in changes of CT numbers
in corresponding voxels, which may affect the dose calculation. This effect likely accounts for the difference (clinically
insignificant) in the optic chiasm DVH concordance. In our
case, MVCT images were acquired with coarse (6 mm) slice
spacing. In the future, we plan to study the effect of scanning with smaller interslice distances on the image quality
and how this improves verification dose calculations. In this
instance, interfaces between bone and air represent a high
contrast situation, thus improvements through adjustment
of slice thickness may improve the correspondence between
plans. In addition, small discrepancies in the registration
that resulted in portions of the PTV residing in air (Fig. 3)
help account for the discrepancy as they result in a calculated underdosage of this portion of the PTV given the lack
of soft tissue buildup. This suggests that in using adaptive
planning for targets that are on the surface, careful review of
the planning contours to ensure there is appropriate mapping
to the current surface is necessary.
The hybrid image based plan for the prostate cancer patient
showed agreement to better than 1% for all parameters when
compared to the kVCT plan (Fig. 1c). Due to the nature of
the region, this is to be expected: while the region is not of
uniform density, only the femurs and portions of the rectum
show large differences in atomic number and densities. The
majority of the contoured structures in the case of prostate
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cancer patients are large enough such that image noise, artifacts, and blurring are averaged and do not affect the plan
in any significant manner. With structures of similar density
arranged in proximity, it is possible that the delineation of the
structures on MVCT images may be more difficult (20). Despite this concern, we noted high concordance between the
PTV1 (prostate only) DVH between the kVCT and hybrid
image plans suggesting contouring differences between the
two studies was not an issue. Likewise, good concordance
between the rectal and bladder DVHs suggested minimal
organ deformation between the kVCT and hybrid images.
There was a noticeable difference between the verification
dose and the planned dose for the PTV2 and seminal vesicle structures as shown in Figure 1c. The seminal vesicles
are more mobile than the prostate and may be more subject
to subtle changes in bladder and rectum volume leading to
variation of dose deposition in the small (and hence more
sensitive to tissue modification) volumes such as the seminal
vesicle and PTV2 contours. To account for this deformation,
modification of the structures should be performed, although
in this preliminary study we assumed that no modification
to the structures occurs between time of kVCT and hybrid
images on the first day of treatment. Alternatively, repeating
the comparison with kVCT and hybrid image done in closer
temporal proximity (i.e., sequentially) may reduce this discrepancy by reducing the possibility of changes in rectal and
bladder filling between studies (21).
There was concern that breathing motion induced artifacts
may lead to some errors in dose calculations in the case of the
lung cancer patients (22); however, our data for this particular case did not show this. In this case the tumor is attached
to mediastunum and probably does not move much. The results in Figure 1a and Table I may indicate that the motion
induced artifacts, which could be different in the fast (gantry
rotation speed of 0.5 s in kVCT) and slow (gantry rotation
speed of 10 s in MVCT), or the blurring of motion, had not
changed the dose distributions significantly. If proved for a
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larger cohort of lung cancer patients (or alternatively if the
upper limit for tumor motion is defined), such insensitivity
to motion artifacts could be very useful for adaptive radiotherapy. In some cases of lung cancer, the tumor will regress
throughout treatment (12-14), allowing for further sparing
of the ipsilateral lung, the contralateral lung, the heart, the
spinal cord, and other OARs. With less dose delivered to
the OARs, complications, such as radiation pneumonitis and
esophagitis, are less likely to occur, thus increasing the overall quality of life of the patients.
The minimum dose to the PTV for the nasal cavity cancer
patient in Table III showed almost a 9% difference, while the
remaining characteristics were below the 2% threshold. The
discrepancy is due to a portion of PTV in air (Fig. 3).
In the case of the brain cancer patient, there were significant
differences in the dose calculations for lenses and the left optic nerve, while the PTV, right optic nerve, and optic chiasm
all showed excellent agreement. Once again, with structures
close to the surface a significant portion of both lenses are
contoured outside of the patient and in air on the merged image, causing the dose calculations for these structures located
near the surface of the patient to be significantly different
(Fig. 4). In the case of the left optic nerve, the minimum dose
may be affected by the blurring of the fine structures when
using MVCT images with 6 mm slice spacing and interpolation. Quantifying the differences in the delineation of fine
structures for head and neck cases in 6, 4, and 2 mm slice
spacing would allow for the best choice in slice spacing to be
made for adaptive planning purposes. It may be that a policy
of 6 mm scanning for daily localization with a repeat finer
(2 or 4 mm scan) scan for adaptive planning (if concerning
anatomy trends are noted on the routine localization scanning) would be a good compromise between daily treatment
efficiency and dose accuracy for adaptive re-planning.
Conclusions
In the case of the lung and prostate cancer patients, there is
good agreement in the calculations of the verification doses
and excellent agreement in the comparison of the hybrid image based plans to the kVCT plans. In these cases, the contoured structures are well within the patient; therefore there
are no adverse effects due to surface dose calculations or
patient deformation. The structures in both these cases are
also fairly large, allowing for image noise and poor contrast
to be averaged out. In both the nasal cavity and brain cancer patients, structures near the surface of the patient caused
some discrepancies in dose calculations on the hybrid image
plan due to small differences between the images. Due to the
decrease in quality of the MVCT image, fine anatomic structures are not as visible, and may cause some discrepancies in
dose calculations. Use of finer resolution MVCT scans for
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adaptive planning in these scenarios may be advisable.
Clinically, verification doses can be used to assess the dose
delivered to patient over the course of treatment and are useful in determining if anatomical changes are clinically relevant. This can be accomplished by adapting structures on the
hybrid image to account for anatomy changes. Since these
patient images are already available, calculation of verification doses offer an additional quality assurance option for
patients treated on tomotherapy. If the anatomical changes
are clinically relevant, Planned Adaptive supplies tools with
which adaptive plans can be created. Future work will focus
on verifying multi-fraction adaptive plans. By using Planned
Adaptive in conjunction with the planning station, more conformal radiation therapy may be possible, along with dose
escalation, further sparing of critical structures, and consequently, higher uncomplicated survival rates.
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